




## IPO NOTE

## GPT HEALTHCARE LIMITED



Rating:  
**NEUTRAL**



## ISSUE OFFER

Issue Opens on	FEB 22, 2024
Issue Close on	FEB 26, 2024
Total IPO size (cr)	₹525.14
Fresh issue (cr)	₹40.00
Offer For Sale (cr)	₹ 485.14
Price Band (INR)	177-186
Market Lot	80
Face Value (INR)	10
Retail Allocation	35%
Listing On	NSE, BSE

## ISSUE BREAK-UP (%)

QIB Portion	<div><div></div></div>	50%
NII Portion	<div><div></div></div>	15%
Retail Portion	<div><div></div></div>	35%

## SHAREHOLDING (No. of Shares)

Pre Issue	Post Issue
79,904,286	82,054,823

## INDICATIVE TIMETABLE

Finalisation of Basis of Allotment	27-02-2024
Refunds/Unblocking ASBA Fund	28-02-2024
Credit of equity shares to DP A/c	28-02-2024
Trading commences	29-02-2024

Under the ILS Hospitals brand, GPT Healthcare Limited manages a network of mid-sized, full-service, multispecialty hospitals in Eastern India that offer integrated healthcare services with an emphasis on secondary and tertiary care. The organization provides a variety of medical treatments across more than 35 specializations and superspecialties.

## OBJECTS OF THE ISSUE

- Payment of certain outstanding borrowings of the company.
- General corporate purposes.

## OUTLOOK &amp; VALUATION

In Eastern India, GPT Healthcare Ltd. (GHL) is a prominent regional corporate healthcare company with respect to the quantity of hospitals and beds. It provides a wide range of medical treatments in more than 35 specializations and super specialties.

The company has strategically concentrated on the comparatively unexplored healthcare industry in Eastern India, where it operates in three cities. The company's location and specialty mixes are both very diversified. On the other hand, the company faces competition from other healthcare service providers and it has a low occupancy rate.

The issue is coming at a PE valuation of 38.1x which seems fairly priced. But considering all the other factors we suggest Investors to carefully evaluate their risk tolerance and conduct further due diligence before making an investment decision.



## KEY MANAGERIAL PERSONNEL

01

### Dwarika Prasad Tantia

Chairman and Whole-time Director of the Company. He graduated from the University of Calcutta in 1974 . He has over 41 years of experience in the infrastructure and healthcare industry. He is the founding member of ILS Hospitals and oversees international business 241 development, project execution and new business ventures.

02

### Dr. Om Tantia

Managing Director of the Company. He has over 40 years of experience as a medical practitioner and has undertaken many laproscopic procedures and has been recognised as a surgeon of excellence by Surgical Review Corporation, USA.

03

### Anurag Tantia

Whole-time Director of the Company. He holds a degree of Bachelor of Science in management with honours from the University of Illinois. He has more than 12 years of experience in healthcare management and looks after the day-to-day operations of the Company.

04


### Kriti Tantia

Chief Financial Officer of the Company. She holds a bachelor's degree in commerce from the University of Calcutta and is a member of the Institute of Chartered Accountants of India (ICAI). She secured an all India rank of 38 in the exam conducted by ICAI.

05

### Ankur Sharma

Company Secretary and Compliance Officer of the Company. Prior to joining the Company, he has completed his training as prescribed by Institute of Company Secretaries of India, with M.K. Sharma & Associates, Practicing Company Secretary and has experience in secretarial and compliance matters.



## COMPANY PROFILE

- The company operates a chain of mid-sized full-service hospitals under the brand ILS and provides integrated healthcare services, with a focus on secondary and tertiary care.
- The company operates four multidisciplinary hospitals with a total capacity of 561 beds.
- The company offers a comprehensive range of healthcare services across over 35 specialties and super specialties, including internal medicine and diabetology, nephrology (including renal transplants), laparoscopic and general surgery, gynecology and obstetrics, critical care, gastroenterology, orthopedics and joint replacements.
- The company strategically focuses on the relatively under-penetrated healthcare market in Eastern India where the company has a presence in three cities.
- The company had 1,855 employees, 85 full-time consultants, and 465 visiting consultants.

## COMPETITIVE STRENGTHS

- Well-diversified specialty mix and location mix
- Ability to attract, train and retain quality medical professionals.
- Track record of operating and financial performance and growth
- Professional management and experienced leadership.
- Strong foothold in under-penetrated and densely populated healthcare delivery markets.
- Strong value proposition for stakeholders

## KEY STRATEGIES

- Strengthen our existing hospitals and their offerings.
- Add new capabilities and specialties.
- Strategically grow presence in adjacent markets.
- Focus on flexible and asset-light expansion for quick break-even.
- Implementation of initiatives to improve existing operational efficiencies

## KEY CONCERNS

- Face competition from other healthcare service providers.
- The bed Occupancy Rate of the Company is lower than some of the listed peers.
- Dependent on certain specialties.
- keep pace with technological changes regularly.
- Highly regulated industry.



## COMPARISON WITH LISTED INDUSTRY PEERS (AS ON 31ST MARCH 2023)

Name of the Company	EPS (Basic)	NAV	P/E	Total Income (Mn)	RoNW (%)
<b>GPT Healthcare Limited</b>	<b>4.88</b>	<b>20.54</b>	<b>-</b>	<b>3,610.37</b>	<b>23.77%</b>
<b>Peer Group</b>					
Global Health Limited	12.57	89.65	90.29	26,942.48	13.56%
Krishna Institute of Medical Sciences Limited	42.03	206.47	49.51	21,976.78	20.35%
Jupiter Life Line Hospitals Limited	12.95	64.70	81.73	8,925.43	19.94%
Yatharth Hospital & Trauma Care Services Limited	10.09	27.84	37.66	5,202.93	36.06%
Kovai Medical Center & Hospital Limited	105.80	656.65	29.93	10,197.47	16.11%
Shalby Limited	6.27	85.54	49.01	8,049.21	7.33%

## FINANCIALS (RESTATED CONSOLIDATED)

PARTICULARS (RS. IN MILLIONS)	FY 2023	FY 2022	FY 2021
<b>Equity Share Capital</b>	799.04	799.04	179.41
<b>Other Equity</b>	854.58	782.78	759.60
<b>Net Worth</b>	1,653.62	1,581.82	1,339.01
<b>Total Borrowings</b>	402.67	724.43	1,022.92
<b>Revenue from Operations</b>	3,610.37	3,374.15	2,427.53
<b>EBITDA</b>	3,667.31	3,424.03	2,488.63
<b>Profit/loss before Tax</b>	559.69	540.79	288.83
<b>Net profit for the year</b>	390.08	416.63	210.93



## DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Ms. Sheetal Duraphe Email: [compliance@swastika.co.in](mailto:compliance@swastika.co.in) Phone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No.: NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532

CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.